MLchartDataset catalogue

AK 3012

Term · Oncology and biomedicine · MLC-T-ONC-009736

A proprietary topical formulation. Upon subcutaneous administration, the active ingredient in AK 3012 may inhibit actinic keratosis.

Table 1. Record
IdentifierMLC-T-ONC-009736
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON 
{
  "id": "MLC-T-ONC-009736",
  "term": "AK 3012",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary topical formulation. Upon subcutaneous administration, the active ingredient in AK 3012 may inhibit actinic keratosis.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ak-3012/"
}

Record 573 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.